Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Med. 2003 Jan;9(1):47-52. Epub 2002 Dec 16.

Cytokine traps: multi-component, high-affinity blockers of cytokine action.

Author information

1
Department of BioMolecular Science, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

Abstract

Cytokines can initiate and perpetuate human diseases, and are among the best-validated of therapeutic targets. Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for cytokines such as interleukin (IL)-1, IL-4, IL-6 and IL-13 that use multi-component receptor systems is limited because monomeric soluble receptors generally exhibit low affinity or function as agonists. We describe here a generally applicable method to create very high-affinity blockers called 'cytokine traps' consisting of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components involved in binding the cytokine. Traps potently block cytokines in vitro and in vivo and represent a substantial advance in creating novel therapeutic candidates for cytokine-driven diseases.

PMID:
12483208
DOI:
10.1038/nm811
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center